[Clinical efficacy of switching to tenofovir amibufenamide tablets with poor response to entecavir in patients with chronic hepatitis B].

<b>Objective:</b> To analyze the clinical efficacy of switching to tenofovir amibufenamide tablets with poor response to entecavir in patients with chronic hepatitis B. <b>Method:</b> Forty patients with chronic hepatitis B who had poor responses to entecavir, admitted to Linyi Central Hospital from July 2021 to July 2024, were selected as the study subjects. Among them, 18 and 22 cases were hepatitis B e antigen (HBeAg) negative and positive, respectively. All patients were treated using tenofovir amibufenamide tablets. The differences in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) prior to treatment, at 12 and 24 weeks of treatment, were compared between HBeAg-negative and positive patients.The hepatitis B virus (HBV) DNA negative conversion rate was compared after 12 and 24 weeks of treatment between HBeAg-negative and positive patients. Statistical analysis was performed using <i>t</i>-test, one-way ANOVA, LSD-<i>t</i> test, and <i>χ</i>² test according to different data. <b>Result:</b> ALT and AST levels were higher in HBeAg-positive than those of HBeAg-negative patients (<i>P</i>＜0.05) prior to treatment. ALT and AST levels were lower in HBeAg-negative and HBeAg-positive patients compared to pre-treatment, while those of HBeAg-negative patients were lower than those of HBeAg-positive patients (<i>P</i>＜0.05) after 12 and 24 weeks of treatment. The HBV DNA negative conversion rate was lower in HBeAg-positive patients than that of HBeAg-negative patients (<i>P</i>＜0.05) after 12 weeks of treatment. There was no statistically significant difference in the HBV DNA conversion rate between HBeAg-positive and HBeAg-negative patients after 24 weeks of treatment (<i>P</i>>0.05). <b>Conclusion:</b> Switching to tenofovir amibufenamide tablets can improve liver function and promote HBV DNA negative conversion with poor response to entecavir in patients with chronic hepatitis B, with better therapeutic effect in HBeAg-negative patients.